Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 4,370 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. This represents a 1.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $12.43 on Friday. The company has a market cap of $1.25 billion, a PE ratio of -12.07 and a beta of -1.46. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.13 and a 1 year high of $18.07. The firm has a 50 day moving average price of $12.37 and a 200 day moving average price of $13.47.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DAWN. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. The Goldman Sachs Group dropped their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, February 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $35.71.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of DAWN. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 87.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,203 shares of the company’s stock worth $267,000 after acquiring an additional 8,935 shares during the period. SteelPeak Wealth LLC boosted its holdings in Day One Biopharmaceuticals by 9.8% in the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock worth $242,000 after acquiring an additional 1,550 shares during the period. TimesSquare Capital Management LLC boosted its holdings in Day One Biopharmaceuticals by 8.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock worth $25,460,000 after acquiring an additional 139,160 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Day One Biopharmaceuticals in the 3rd quarter worth approximately $825,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.